Evidence map›Paper›PMID 41397968›Full record

ArticleNature communications2025

Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state.

Ludivine Bersier, L Francisco Lorenzo-Martin, Yi-Hsuan Chiang, Stephan Durot, Aleksander Czauderna, Tural Yarahmadov, Tania Wyss Lozano, Irena Roci, Jaeryung Kim, Nicola Zamboni and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ludivine BersierDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0009-0002-1695-3626
L Francisco Lorenzo-MartinLaboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-4717-9338
Yi-Hsuan ChiangDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.
Stephan DurotInstitute of Molecular Systems Biology, Department of Biology, ETH Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-2307-7070
Aleksander CzaudernaDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Tural YarahmadovDepartment of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Tania Wyss LozanoDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2641-0895
Irena RociDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9522-0641
Jaeryung KimDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-8003-5849
Nicola ZamboniInstitute of Molecular Systems Biology, Department of Biology, ETH Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-1271-1021
Nicola VanniniDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6351-7512
Caroline PotService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1146-3129
Tinh-Hai ColletService of Endocrinology, Diabetes and Metabolism, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-3243-1222
Deborah StrokaDepartment of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-3517-3871
Jeremiah Bernier-LatmaniDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6407-1049
Matthias P LutolfLaboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-5898-305X
Simone BecattiniDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Thibaud KoesslerCenter for Translational Research in Oncology-Hematology, Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-9196-9076
Tatiana V PetrovaDepartment of Fundamental Oncology, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Lausanne, Switzerland. tatiana.petrova@unil.ch.ORCID http://orcid.org/0000-0002-0563-6521

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 32003B-212559Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) PCEFP3_187018Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) PZ00P3-167826Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF 10003598Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF 316030_183501Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) TMSGI3_211235
6 · The paper itself

Abstract

The contribution of chemotherapy-induced tissue injury to individual susceptibility to metastasis remains largely unexplored. We report that chemotherapy indirectly prevents colorectal cancer (CRC) liver metastases by inducing a lasting systemic "chemomemory". Chemotherapy-induced intestinal mucositis alters nutrient availability, promoting the expansion of tryptophan-metabolizing bacteria and production of the microbial metabolite indole-3-propionic acid (IPA). IPA reprograms bone marrow myelopoiesis by redirecting common myeloid progenitor fate toward the macrophage lineage, limiting generation of immunosuppressive Ly6C

Indexed as

Antimetabolites, AntineoplasticColorectal NeoplasmsDysbiosisGastrointestinal MicrobiomeIntestinesLiver NeoplasmsMyelopoiesisAnimalsCD4-Positive T-LymphocytesFemaleFluorouracilHumansIndolesMaleMiceMice, Inbred C57BLAntimetabolites, AntineoplasticFluorouracilindolepropionic acidIndoles

Identifiers

PMID41397968
PMCPMC12827274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.